share_log

G Medical Innovations Holdings Ltd. Announces Closing of Public Offering

G Medical Innovations Holdings Ltd. Announces Closing of Public Offering

G Medical Innovations Holdings Ltd
GlobeNewswire ·  2023/04/05 04:05

Rehovot, Israel, April 04, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the "Company"), a global leader in next-generation mobile health (mHealth) and digital health, today announced the closing of its public offering of 12,000,000 ordinary shares (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof), each sold to the public at a price of $0.80 (inclusive of the exercise price of the Pre-Funded Warrant) for gross proceeds of approximately $9.6 million, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,800,000 ordinary shares and/or Pre-Funded Warrants to cover over-allotments at the public offering price, less the underwriting discount.

以色列雷霍沃特,2023年4月4日(GLOBE NEWSWIRE)——下一代移动健康(mHealth)和数字健康领域的全球领导者G Medical Innovations Holdings Ltd.(纳斯达克股票代码:GMVD)(“公司”)今天宣布完成12,000,000股普通股(或代替预融资认股权证(“预融资认股权证”)的公开发行,每股向公众出售在扣除承保折扣和发行费用之前,总收益约为960万美元(包括预付认股权证的行使价)0.80美元。此外,公司还授予承销商45天的期权,允许承销商额外购买最多1,800,000股普通股和/或预融资认股权证,以公开发行价格减去承销折扣后的超额配股。

The Company intends to use the net proceeds for general corporate purposes (including financing operations, capital expenditures and business development), the repayment in full of the April 2021 Financing Debentures, and potential mergers or acquisitions.

公司打算将所得净额用于一般公司用途(包括融资业务、资本支出和业务发展)、全额偿还2021年4月的融资债券以及潜在的合并或收购。

ThinkEquity acted as sole book-running manager for the offering.

ThinkeQuity是本次发行的唯一账簿管理人。

A registration statement on Form F-1 (File No. 333-269496) relating to the shares was filed with the Securities and Exchange Commission (the "SEC") and became effective on March 31, 2023. This offering has been made only by means of a prospectus. An electronic copy of the final prospectus disclosing the final terms of the offering has been filed with the SEC and may be obtained on the SEC's website at www.sec.gov, and may also be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at prospectus@think-equity.com.

与股票有关的F-1表格(文件编号333-269496)的注册声明已提交给美国证券交易委员会(“SEC”),并于2023年3月31日生效。本次发行仅通过招股说明书进行。披露本次发行最终条款的最终招股说明书的电子副本已提交给美国证券交易委员会,可在美国证券交易委员会网站www.sec.gov上获得,也可以从位于州街17号41号的ThinkeQuity获得st Floor,纽约,纽约 10004,致电 (877) 436-3673,发送电子邮件至 prospectus@think-equity.com。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约或招揽买入要约,在根据任何此类州或司法管辖区的证券法进行注册或资格认证之前,此类要约、招标或出售是非法的州或司法管辖区也不得出售这些证券。

About G Medical Innovations Holdings Ltd.
G Medical Innovations Holdings Ltd. is a healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company's solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company's current product lines consist of its Prizma medical device (or Prizma), a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter and Monitoring Cardiac Telemetry Patch services, utilizing a multi-channel patient-worn biosensors, with algorithms for real time analysis and transmission that captures electrocardiography (i.e. ECG) data continuously, including QT Syndrome Prolongation Detection. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (i.e., IDTF) monitoring services and private monitoring services.

关于 G 医疗创新控股有限公司
G Medical Innovations Holdings Ltd.是一家医疗保健公司,从事下一代移动医疗和远程医疗解决方案和监控服务平台的开发。该公司的解决方案和服务可以使消费者、患者和提供者能够更好地监测、管理和改善临床和个人健康结果,尤其是那些患有心血管疾病(或CVD)、肺部疾病和糖尿病的人。该公司目前的产品线包括其Prizma医疗设备(或Prizma),这是一种临床级设备,几乎可以将任何智能手机转变为医疗监测设备,使医疗保健提供者和个人都能监测、管理和共享各种生命体征和生物识别指标;其扩展动态心电图和监测心脏遥测补丁服务,使用多通道患者佩戴的生物传感器,具有捕获心电图的实时分析和传输算法连续的造影(即心电图)数据,包括QT 综合征延期检测。此外,该公司正在开发其无线生命体征监测系统(或VSMS),预计该系统将对各种生命体征和生物识别提供全面、持续和实时的监测。其监测服务包括提供独立诊断测试设施(即IDTF)监测服务和私人监测服务。

In the second half of 2022, the Company expanded its business activities into a new business area, at-home laboratory testing kits. In the third quarter of 2023, the Company expects that users will be able to purchase a sample collection kit at retail stores or online and collect their sample from the comfort and privacy of their home and send it via mail to the Company's certified lab for analysis. The Company has developed 31 types of tests kits which can test a wide range health issued related to hormones, sexual transferred disease, colon cancer, nutrition, food sensitivities and allergies. In addition, the Company's pipeline includes development of additional kits for drug detection, heavy metal and toxicology. Data received from both vital signs and lab tests reflects the vision of the Company which is to allow users to create their personal electronic medical records and manage their health in one location which is available for them anywhere and anytime without dependency on any medical organization.

2022 年下半年,公司将其业务活动扩展到一个新的业务领域,即家用实验室测试套件。该公司预计,在2023年第三季度,用户将能够在零售商店或网上购买样本采集套件,在家中舒适和私密地收集样本,并通过邮件将其发送到公司的认证实验室进行分析。该公司开发了31种检测试剂盒,可以测试与激素、性转移疾病、结肠癌、营养、食物敏感和过敏有关的各种健康问题。此外,该公司的产品线还包括开发其他药物检测、重金属和毒理学试剂盒。从生命体征和实验室测试中获得的数据反映了公司的愿景,即允许用户创建个人电子病历并在一个地点管理他们的健康状况,这些记录可供他们随时随地使用,而无需依赖任何医疗组织。

For more information about G Medical innovations, visit

有关 G Medical 创新的更多信息,请访问

Forward Looking Statements

前瞻性陈述

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on G Medical Innovations Holdings Ltd.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and G Medical Innovations Holdings Ltd. undertakes no duty to update such information except as required under applicable law.

本新闻稿包含受重大风险和不确定性影响的 “前瞻性陈述”。本新闻稿中包含的所有陈述,除历史事实陈述外,均为前瞻性陈述。本新闻稿中包含的前瞻性陈述可以通过使用 “预期”、“相信”、“考虑”、“可以”、“估计”、“期望”、“打算”、“寻求”、“可能”、“可能”、“计划”、“潜力”、“预测”、“项目”、“目标”、“目标”、“应该”、“将” 或尽管并非所有前瞻性陈述都包含这些词语,但对这些词语或其他类似表达方式持否定态度。前瞻性陈述基于G Medical Innovations控股有限公司。”的当前预期,受难以预测的固有不确定性、风险和假设的影响。此外,某些前瞻性陈述基于对未来事件的假设,这些假设可能并不准确。在向美国证券交易委员会提交的与公开发行有关的最终招股说明书中,标题为 “风险因素” 的部分对这些以及其他风险和不确定性进行了更全面的描述。本公告中包含的前瞻性陈述自该日起作出,除非适用法律要求,否则G Medical Innovations Holdings Ltd.没有义务更新此类信息。

Investor Relations Contact:
service@gmedinnovations.com

投资者关系联系人:
service@gmedinnovations.com


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发